Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

FGFR2

RBC: FGFR2 · Substrate: pEY + Mn ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Ponatinib99.40.53
Futibatinib99.30.72
Erdafitinib99.00.74
Alpelisib98.90.72
Infigratinib98.80.71
Pemigatinib98.70.72
Nintedanib97.00.61
Axitinib96.10.69
Brigatinib96.10.51
Tenalisib96.00.70
Selpercatinib95.00.64
Pralsetinib93.20.64
Deucravacitinib92.50.72
Vandetanib90.80.72
Pazopanib88.90.67

Known variants

Cancer associations

MutationCancer typeOrganSource
E565Acarcinoma_biliary_tractBiliary Tracthttps://doi.org/10.1093/nar/gkaa945
C491Aendometrial_carcinomaUterushttps://www.cancer.gov/tcga.
C491Acarcinoma_liverLiverhttps://www.cancer.gov/tcga.
C491Fendometrial_carcinomaUterushttps://doi.org/10.1158/2159-8290.CD-12-0095
C491Fcarcinoma_liverLiverhttps://www.cancer.gov/tcga.
C491Sendometrial_carcinomaUterushttps://doi.org/10.1158/2159-8290.CD-12-0095
C491Scarcinoma_liverLiverhttps://depmap.org/portal.
E565Gendometrial_carcinomaUterushttps://doi.org/10.1158/2159-8290.CD-12-0095
E565Gcarcinoma_liverLiverhttps://doi.org/10.1158/2159-8290.CD-12-0095
K526Eendometrial_carcinomaUterushttps://depmap.org/portal.
K526Ecarcinoma_liverLiverhttps://depmap.org/portal.
M420Iendometrial_carcinomaUterushttps://depmap.org/portal.
M420Icarcinoma_liverLiverhttps://doi.org/10.1158/2159-8290.CD-12-0095
V564Iendometrial_carcinomaUterushttps://doi.org/10.1158/2159-8290.CD-12-0095
V564Icarcinoma_liverLiverhttps://www.cancer.gov/tcga.
V564Lendometrial_carcinomaUterushttps://ckb.genomenon.com/geneVariant/show?geneVariantId=26132
V564Lcarcinoma_liverLiverhttps://ckb.genomenon.com/geneVariant/show?geneVariantId=26133
K641Rcarcinoma_biliary_tractBiliary Tracthttps://doi.org/10.1093/nar/gkaa945
K641Rcarcinoma_salivary_glandSalivary Glandhttps://doi.org/10.1093/nar/gkaa945
K659Ncarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
Open in new tab